Loading organizations...
§ Venture Capital · USA
Learn which startups Stray Dog Capital invests in, what size check sizes they write, and who their partners are (e.g. Lisa Feria).
Key people at Stray Dog Capital.
Stray Dog Capital operates as a venture capital firm, specializing in early-stage investments across the food, beverage, and biotechnology sectors. The firm identifies and supports innovative companies developing alternative protein sources and sustainable solutions. Its strategy targets enterprises poised to disrupt traditional industries and meet evolving consumer demands for ethical products.
Chuck Laue and Jennifer Laue co-founded Stray Dog Capital in 2015. Their insight stemmed from recognizing the burgeoning global demand for plant-based and alternative options. They identified a market opportunity and critical need for capital to scale businesses transforming the food system toward humane and sustainable practices.
The firm's portfolio comprises early-stage innovators seeking capital and strategic partnership. Stray Dog Capital envisions a future food system that is sustainable, humane, and efficient. It accelerates growth for companies contributing to this paradigm shift, driving progress toward a globally impactful and responsible economy.
Key people at Stray Dog Capital.
Stray Dog Capital is a mission-driven venture capital firm focused on investing in early-stage companies within the food, beverage, and biotechnology sectors, particularly those advancing plant-based, cellular agriculture, and food technology innovations. Their mission centers on fostering healthier, more humane, and sustainable food systems by supporting transformative startups that eliminate animal use and promote ethical practices. The firm primarily invests at the seed and Series A stages, aiming to align financial returns with positive social and environmental impact, thus driving meaningful change in the food ecosystem[1][2][3].
Founded in 2015 and headquartered in Leawood, Kansas, Stray Dog Capital was established by partners including Johnny Ream and Lisa Feria, who bring extensive experience in venture investing and sector expertise. The firm has evolved to specialize in early-stage investments that leverage biotechnology and innovative food technologies to disrupt traditional animal agriculture. Over time, Stray Dog Capital has built a portfolio of over 40 companies, including notable investments in plant-based meat, fermentation-based proteins, and food waste reduction platforms, reflecting its commitment to scalable impact and innovation[1][3][5].
Stray Dog Capital rides the rising trend of sustainable food innovation, capitalizing on growing consumer demand for plant-based and alternative protein products driven by health, environmental, and ethical concerns. The timing is critical as biotechnology and food tech mature, enabling scalable alternatives to traditional animal agriculture. Market forces such as climate change awareness, regulatory shifts, and shifting dietary preferences favor the firm’s investment thesis. By backing pioneering startups, Stray Dog Capital influences the broader ecosystem by accelerating the transition to sustainable food production and fostering a new generation of food tech entrepreneurs[1][2][3].
Looking ahead, Stray Dog Capital is poised to deepen its impact by continuing to invest in cutting-edge food and biotech startups that address global challenges related to health, sustainability, and animal welfare. Trends such as cellular agriculture, fermentation technologies, and AI-driven food innovation will likely shape their portfolio’s evolution. As the alternative protein market expands and consumer adoption grows, Stray Dog Capital’s influence is expected to increase, positioning it as a key player in the transformation of the global food system[1][2][3][5]. Their commitment to aligning ethical responsibility with financial success will remain central to their strategy, driving both innovation and impact in the years to come.
Stray Dog Capital has 26 tracked investments across 22 companies. The latest tracked deal is $2.8M Seed in Cascade Biocatalysts in September 2025.
